Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli

Journal of Infection and Chemotherapy

Volumn 15, Issue 1, 2009, Pages 13-17

  Nakamura, Tatsuya ^a,b   Shimizu, Chihiro ^a   Kasahara, Mayumi ^a   Okuda, Kazuyuki ^a   Nakata, Chiyo ^a   Fujimoto, Hiroko ^a   Okura, Hiroe ^a   Komatsu, Masaru ^c   Shimakawa, Kouichi ^d   Sueyoshi, Noriyuki ^e   Ura, Toshiro ^f   Satoh, Kaori ^g   Toyokawa, Masahiro ^h   Wada, Yasunao ⁱ   Orita, Tamaki ^j   Kofuku, Tomomi ^k   Yamasaki, Katsutoshi ^l   Sakamoto, Masako ^m   Nishio, Hisaaki ⁿ   Kinoshita, Shohiro ^o   Takahashi, Hakuo ^a,p   more..

^a KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c FALCO Biosystems Ltd   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

^e Social Insurance Shiga Hospital   (Japan)

^f NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OSAKA UNIVERSITY HOSPITAL   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

^j Takarazuka Municipal Hospital   (Japan)

^k HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^l WAKAYAMA ROSAI HOSPITAL   (Japan)

^m The Research Foundation for Microbial Diseases of Osaka University   (Japan)

ⁿ Shiga Medical Center for Adults   (Japan)

^o KOBE UNIVERSITY HOSPITAL   (Japan)

^p KANSAI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Carbapenem; Escherichia. coli; Extended spectrum lactamase(ESBL); Fluoroquinolone; Monte Carlo simulation; Pharmacokinetic pharmacodynamic (PK PD)

Indexed keywords

ANTIBIOTIC AGENT; BIAPENEM; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PAZUFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ULIFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHASE 1 CLINICAL TRIAL; PROBABILITY;

EID: 62449287352     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-008-0656-6     Document Type: Article

References (22)

1. K. Bush G.A. Jacoby A.A. Medeiros 1995 A functional classification scheme for beta-lactamases and its correlation with molecular structure Antimicrob Agents Chemother 39 1211 1233
2. D.L. Paterson W.C. Ko A. Von Gottberg S. Mohapatra J.M. Casellas H. Goossens 2004 International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum betalactamase production in nosocomial infections Ann Intern Med 140 26 32
3. P.L. Winokur R. Canton J.M. Casellas N. Legakis 2001 Variations in the prevalence of strains expressing an extended-spectrum betalactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region Clin Infect Dis 32 94 103
4. J. Wiener J.P. Quinn P.A. Bradford R.V. Goering C. Nathan K. Bush 1999 Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes JAMA 281 517 523
5. R. Colodner W. Rock B. Chazan N. Keller N. Guy W. Sakran 2004 Risk factors for the development of extended-spectrum betalactamase-producing bacteria in nonhospitalized patients Eur J Clin Microbiol Infect Dis 23 163 167
6. J.D. Pitout N.D. Hanson D.L. Church K.B. Laupland 2004 Populationbased laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes Clin Infect Dis 38 1736 1741
7. W.A. Craig 1998 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1 10
8. M. Nakashima 2005 Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers Chemotherapy 53 S-1 104 123
9. A. Saito 1994 Pharmacokinetic study on biapenem Chemotherapy 42 S-4 277 284
10. A. Saito 1985 Studies on imipenem/cilastatin sodium (MK-0787/MK-0791) Chemotherapy 33 S-4 379 391
11. A. Saito 1992 Pharmacokinetic study on meropenem Chemotherapy 40 S-1 276 282
12. H. Kobayashi M. Shimura 1985 Phase I study with BAY o 9867(cipro-floxacin) Chemotherapy 33 S-7 140 170
13. M. Nakajima T. Uematsu K. Kosuga K. Uemura 1999 Phase 1 study of gatifloxacin, new quinolone Chemotherapy 48 175 207
14. M. Nakajima T. Uematsu K. Kosuga K. Uemura 1999 Phase 1 clinical study of pasufloxacin mesilate Jpn J Chemotherapy 47 175 206
15. Y. Okuyama K. Momota A. Morino 1997 Pharmacokinetics of prulifloxacin. First communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration Arzneimittelforschung 47 276 284
16. C. Okazaki H. Kojima M. Hakusui M. Nakashima 1991 Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother 35 2106 2109
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. M100-S15. Wayne PA: Clinical and Laboratory Standards Institute; 2005.
18. D.L. Paterson W.C. Ko A. Von Gottberg S. Mohapatra J.M. Casellas H. Goossens 2004 Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases Clin Infect Dis 39 31 37
19. J.L. Kuti C.H. Nightingale D.P. Nicolau 2004 Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002 Antimicrob Agents Chemother 48 2464 2470
20. W.A. Craig 2001 Does the dose matter? Clin Infect Dis 33 233 237
21. A. Forrest D.E. Nix C.H. Ballow T.F. Goss M.C. Birmingham J.J. Schentag 1993 Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 1073 1081
22. L.R. Moczygemba C.R. Frei D.S. Burgess 2004 Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases Clin Ther 26 1800 1807